- Home
- ROOT vs SRPT Comparison
ROOT vs SRPT Comparison
Compare ROOT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- SRPT
- Stock Information
- Founded
- ROOT 2015
- SRPT 1980
- Country
- ROOT United States
- SRPT United States
- Employees
- ROOT N/A
- SRPT N/A
- Industry
- ROOT Property-Casualty Insurers
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- SRPT Health Care
- Exchange
- ROOT Nasdaq
- SRPT Nasdaq
- Market Cap
- ROOT 2.3B
- SRPT 2.0B
- IPO Year
- ROOT 2020
- SRPT 1997
- Fundamental
- Price
- ROOT $98.81
- SRPT $17.34
- Analyst Decision
- ROOT Buy
- SRPT Hold
- Analyst Count
- ROOT 6
- SRPT 31
- Target Price
- ROOT $130.60
- SRPT $43.32
- AVG Volume (30 Days)
- ROOT 472.7K
- SRPT 8.2M
- Earning Date
- ROOT 10-29-2025
- SRPT 11-05-2025
- Dividend Yield
- ROOT N/A
- SRPT N/A
- EPS Growth
- ROOT N/A
- SRPT N/A
- EPS
- ROOT 4.73
- SRPT N/A
- Revenue
- ROOT $1,364,700,000.00
- SRPT $2,481,531,000.00
- Revenue This Year
- ROOT $27.16
- SRPT $9.41
- Revenue Next Year
- ROOT $9.22
- SRPT N/A
- P/E Ratio
- ROOT $21.07
- SRPT N/A
- Revenue Growth
- ROOT 59.76
- SRPT 64.89
- 52 Week Low
- ROOT $34.04
- SRPT $10.42
- 52 Week High
- ROOT $181.14
- SRPT $138.81
- Technical
- Relative Strength Index (RSI)
- ROOT 51.84
- SRPT 43.53
- Support Level
- ROOT $94.64
- SRPT $16.85
- Resistance Level
- ROOT $102.44
- SRPT $19.27
- Average True Range (ATR)
- ROOT 4.49
- SRPT 1.02
- MACD
- ROOT 2.27
- SRPT -0.14
- Stochastic Oscillator
- ROOT 78.80
- SRPT 14.00
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.